Brief: Newron Pharmaceuticals Provides Update On Regulatory Status Of Evenamide
28/05/2019 06:14
May 28 (Reuters) - Newron Pharmaceuticals SpA NWRN.S :
* PROVIDES UPDATE ON REGULATORY STATUS OF EVENAMIDE FOR
TREATMENT
OF SCHIZOPHRENIA
* NEWRON PHARMACEUTICALS - RECEIVED A COMMUNICATION FROM FDA
INDICATING CONCERN ON FINDINGS FROM A RECENTLY COMPLETED STUDY
IN RATS AS WELL AS CNS EVENTS AT HIGHER DOSES IN DOGS
Source text: https://bit.ly/2VWY0tz
Further company coverage: NWRN.S
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study